Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Corporate Presentation - DrDR Is AWOL!!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(370)
•••
Comment by OttawaPeteron Jan 25, 2023 11:09am
107 Views
Post# 35245156

RE:RE:RE:RE:Corporate Presentation - DrDR Is AWOL!!

RE:RE:RE:RE:Corporate Presentation - DrDR Is AWOL!!

zwerp2000 wrote: Shake up how? Isn't it too late? BTI has no money and debt obligations coming due very soon. How will they be paid? They do not seem to have any access to capital. Won't they default on these debts? For years this company did nothing and now they are going to face the music 

 

I'm starting to think you work for one of the companies Bioasis owes debt to & would benefit from a default on the loan so are therefore attempting to manipulate SHs with your inane, repetitive comments-- otherwise what is point of you being on here with your doom & gloom? Do you even own BTI shares? You've offered nothing constructive & seem to be another troll with an anger management problem-- not healthy. 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities